Studies of the medicinal properties of buckthorn were started in the 80s of the twentieth century. To date, about 20 studies have examined the clinical effects of Erebra®, the active ingredient of which is a high-tech extract of sea buckthorn leaves.
The work confirms the great therapeutic potential of sea buckthorn leaf extract, its:
- cardio-, hepato-, radioprotective,
- immunomodulatory activity
In Ukraine, clinical trials of hyporamine (Erebra) were conducted in 2013-2016 in many clinics in Kyiv, Lviv, Poltava, Odessa. All of them confirmed the high effectiveness of the antiviral drug Erebra® with a reduced risk of secondary bacterial complications (2.4 times) and the risk of recurrent SARS (2 times). In addition, all tests showed that Erebra® has no allergic effect, the drug has no mutagenic, embryotoxic, teratogenic effect, is a low-toxic substances, and does not cause changes in immune status.